Go to Homepage Back to article list

Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis

Blauvelt A, Kircik L, Papp K, et al. 2022.
Read full article Share Share

Articles are owned by their respective copyright owners. Review publisher's permissions and terms of use for each article.

IMPORTANT INFORMATION FOR READERS

This reprint contains information not included in the FDA-approved labeling for OPZELURA™ (ruxolitinib) cream 1.5%.
  • TRuE-AD1 and TRuE-AD2 were identically designed, double-blind, randomized, vehicle-controlled trials.
  • Data in the analyses included in this article were pooled from TRuE-AD1 and TRuE-AD2 for all endpoints (VC period) and analyzed by descriptive statistics.
  • Incyte Corporation conducted a comprehensive literature search at time of publication and did not identify any publications with contrary results.